London party

Akari Therapeutics to Attend Jefferies London Healthcare Conference

Akari Therapeutics Plc

NEW YORK and LONDON, Nov. 09, 2022 (GLOBE NEWSWIRE) — Akari Therapeutics, Plc (Nasdaq: AKTX), a late-stage biotechnology company developing advanced therapies for autoimmune and inflammatory diseases, today announced that the company will attend the Jefferies London Healthcare conference is scheduled to take place November 15-17, 2022. Chief Executive Officer Rachelle Jacques and Akari’s management team will attend one-on-one meetings with registered investors at the conference.

About Akari Therapeutics

Akari Therapeutics, plc (Nasdaq: AKTX) is a biotechnology company that develops advanced therapies for autoimmune and inflammatory diseases. Akari’s main active ingredient, experimental nomacopan, is a bispecific recombinant inhibitor of complement C5 activation and leukotriene B4 (LTB4) activity. Akari’s pipeline includes a Phase 3 clinical trial program of nomacopan for severe pediatric thrombotic microangiopathy related to hematopoietic stem cell transplantation (HSCT-TMA), as well as preclinical research of PAS-nomacopan at prolonged action in geographic atrophy (GA). For more information about Akari, please visit

Caution Regarding Forward-Looking Statements

Certain statements in this press release constitute “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements reflect our current beliefs about our plans, intentions, expectations, strategies and prospects, which are on the based on the information currently available to us and the assumptions we have made. Although we believe that our plans, intentions, expectations, strategies and prospects, as reflected or implied by these forward-looking statements, are reasonable, we cannot guarantee that the plans, intentions, expectations or strategies will be achieved or achieved. In addition, actual results may differ materially from those described in the forward-looking statements and will be affected by a variety of risks and factors beyond our control. These risks and uncertainties to our company include, but are not limited to: additional capital requirements to fund our operations; our ability to continue our business; cash flow uncertainties and the inability to meet working capital requirements; an inability or delay in obtaining required regulatory approvals for nomacopan and any other product candidates, which may result in unforeseen expenses; our ability to obtain orphan drug designation in additional indications; risks inherent in drug development generally; uncertainties regarding the achievement of positive clinical results for nomacopan and any other product candidates and the unexpected costs that may result; difficulties in recruiting patients into our clinical trials; the inability to realize any value from nomacopan and any other product candidates developed and under development in light of the inherent risks and difficulties inherent in bringing product candidates to market; failure to develop new product candidates and support existing product candidates; approval by the FDA and EMA and any other similar foreign regulatory authority of other competing or superior products brought to market; risks resulting from unforeseen side effects; the risk that the market for nomacopan will not be as large as expected; risks associated with the impact of the COVID-19 pandemic; the inability to obtain, maintain and enforce patents and other intellectual property rights or the unforeseen costs associated with such application or litigation; the inability to obtain and maintain commercial manufacturing agreements with third-party manufacturers or establish commercial-scale manufacturing capabilities; the inability to timely source adequate quantities of our active pharmaceutical ingredients from third-party manufacturers on which the Company depends; unexpected cost increases and pricing pressures and risks and other risk factors detailed in our public filings with the United States Securities and Exchange Commission, including our most recently filed Annual Report on Form 20-F filed with the DRY. Unless otherwise stated, these forward-looking statements speak only as of the date of this press release, and we undertake no obligation to update or revise any of these statements to reflect events or circumstances occurring after such date. Press release. We caution investors not to place significant reliance on any forward-looking statements contained in this press release.

For more information

Investor contacts:
mike moyer
LifeSci Advisors
(617) 308-4306
[email protected]

Media Contact:
Eliza Schleifstein
RP Schleifstein
(917) 763-8106
[email protected]